When cell and gene therapies were coming as one at a time, initially for rare diseases, the impact on payers could be minimized. But now that a big wave of regenerative medicines for a wider array of diseases is hitting the commercial market, they could have a significant impact on the bottom line, companies acknowledged during the Alliance for Regenerative Medicine's (ARM's) recent Cell and Gene Meeting on the Mesa.
Given the complicated nature of these products, cell and gene therapy developers emphasized the importance of engaging with payers early...








